

Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity

VOJTECH HAINER, MD, PHD

Obesity and overweight are reaching global epidemic proportions affecting more than 1.1 billion individuals worldwide. Excess weight is associated with an increased mortality, chronic morbidity (including type 2 diabetes, arterial hypertension, cardiovascular diseases, and certain cancers), decreased quality of life, and considerable health care costs (1).

Antiobesity drugs work through different mechanisms either in the central nervous system (CNS) or in the peripheral tissues. These mechanisms include: 1) suppression of food intake in the CNS, 2) decreased gut absorption of nutrients, and 3) increased energy expenditure or oxidation of nutrients. The efficacy of antiobesity drugs should be evaluated by their ability to reduce fat stores (preferentially visceral adipose tissue), maintain weight loss, diminish obesity-related health risks, and thus decrease morbidity and mortality, and improve quality of life. An ideal antiobesity drug should be administered orally, devoid of major side effects, and distributed at affordable price. Treatment with antiobesity drugs can be considered in obese patients who failed to achieve a sufficient weight loss to a program of lifestyle change, diet, and physical activity. However, the drug treatment of obesity should be an integral part of the comprehensive obesity treatment program that includes diet, exercise, and cognitive behavioral intervention (2,3). Treatment of obesity should be individually tailored taking into account the degree and character of obesity, age, sex,

and the presence of comorbidities (4). Drugs used for the treatment of obesity in the past were associated with serious side effects (psycho-stimulatory, depression, addiction, cardio-excitatory effects, pulmonary hypertension, and valve disease). Antiobesity agents that possess cardio-excitatory and psycho-stimulatory effects (e.g., phentermine, ephedrine, and caffeine mixture) have still been available for the short-term use in some countries (<3 months).

SIBUTRAMINE AND ORLISTAT—

Currently, only two drugs, sibutramine and orlistat, are prescribed for long-term administration. The most important trial evaluating the long-term efficacy of sibutramine was the Sibutramine Trial of Obesity Reduction and Maintenance (STORM) in duration of 2 years (5), while the XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study assessing orlistat efficacy in preventing type 2 diabetes in obese subjects was carried out over a 4-year period (6). Meta-analysis of randomized trials revealed that sibutramine led to 4.2 kg and orlistat to 2.9 kg weight reduction in comparison with placebo (7). Four of the seven studies comparing sibutramine and orlistat monotherapy showed that sibutramine was significantly more efficacious for weight loss, and the remaining three studies showed equivalent effects (8). Modest weight loss (5–10%) in response to antiobesity drug treatment was associated with an improvement in lipid and glycemic profile. Sibutramine

improved concentrations of HDL cholesterol and triglycerides, whereas orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and LDL cholesterol (7). Norris et al. (9) conducted a meta-analysis on the efficacy of orlistat and sibutramine in obese adults with type 2 diabetes and found only modest reductions of glycated hemoglobin (0.4% with orlistat, 0.7% with sibutramine). The improvement in lipid profile in response to sibutramine and orlistat is greater than can be expected from weight loss per se. A systemic review and a meta-analysis on attrition rate in trials with weight loss medications reported either similar total dropout rate for orlistat and sibutramine (10) or somewhat lower dropout rate on sibutramine (8).

The sibutramine treatment favorably affects inflammatory cytokines, serum hormonal levels (resistin, adiponectin), and the transport of leptin through the blood-brain barrier. Antiobesity effects and adverse events are related to the mechanisms of action of both drugs. Sibutramine selectively inhibits reuptake of serotonin, norepinephrine, and partly dopamine in the hypothalamus. This action results in an enhanced satiety and slightly increased thermogenesis (11). Orlistat reduces dietary fat absorption by inhibition of gastrointestinal and pancreatic lipase. The peripheral sympathomimetic activity of sibutramine leads to an increase in both systolic (sBP) and diastolic blood pressure (dBp) and pulse rate. However combined analysis of two placebo-controlled trials concluded that sibutramine treatment is unlikely to elicit a critical increase in blood pressure even in hypertensive patients with well-controlled hypertension. This is explained by the clonidine-like effect of sibutramine, which is mediated through activation of central α -2 adrenoreceptors (12). A recent meta-analysis of long-term changes in blood pressure following orlistat (12 trials including 5,540 patients) and sibutramine (6 trials including 1,495 patients) treatment in placebo-controlled trials of 12-months duration revealed a

From the Institute of Endocrinology, Obesity Management Center, Prague, Czech Republic.

Corresponding author: Vojtech Hainer, vhainer@endo.cz.

This publication is based on the presentations at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this supplement were made possible in part by unrestricted educational grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Ethicon Endo-Surgery, Genex Biotechnology, F. Hoffmann-La Roche, Janssen-Cilag, Johnson & Johnson, Novo Nordisk, Medtronic, and Pfizer.

DOI: 10.2337/dc11-s255

© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

modest decrease in both sBP (−1.9 mmHg) and dBP (−1.5 mmHg) in response to orlistat treatment, whereas sibutramine treatment led to a modest increase in sBP (+0.5 mmHg) and dBP (+1.7 mmHg) (13). It should be pointed out that the reduction of blood pressure in patients with type 2 diabetes after orlistat treatment was less pronounced and the increase in blood pressure after sibutramine was higher. A recent experience from the Sibutramine Cardiovascular Outcomes (SCOUT) trial clearly indicated that sibutramine administration should be strictly avoided in patients with a history of cardiovascular disease, including those with uncontrolled hypertension (14,15).

Ten years of experiences with sibutramine and orlistat in the treatment of obesity and related conditions in both adults and adolescents were recently reviewed (16–18). In addition to obesity, the efficacy and safety of both drugs in the treatment of nonalcoholic fatty liver disease, polycystic ovary syndrome, and binge eating disorder were reported. Improvement in health-related quality of life was shown in sibutramine-treated patients who achieved moderate weight loss (19). Sibutramine treatment-induced weight loss is associated with improvement in eating attitudes as documented by increased dietary restraint and decreased dietary disinhibition and hunger scores (20). The weight loss with orlistat is not related to eating behavior attitudes but is associated with personality traits such as “order” and “deliberation” and thus, in contrast to sibutramine, is more demanding and requires greater adherence (21).

Orlistat inhibits gastrointestinal and pancreatic lipase and thus the weight loss and favorable metabolic effects are mainly achieved by 30% reduction in dietary fat absorption. Because of the insignificant intestinal absorption and subsequent low bioavailability of orlistat, both its anti-obesity effects and side effects (steatorrhea, oily spotting, fecal incontinence) are mediated via the gastrointestinal tract. The administration of orlistat is contraindicated in patients with malabsorption syndrome and cholestasis. Until now, no definite association between liver injury and orlistat administration has been established. Orlistat blocks the absorption of fat-soluble vitamins and β -carotene, and thus their substitution is recommended during the long-term administration of orlistat.

IS TESOFENSINE THE SUCCESSOR OF SIBUTRAMINE?

Tesofensine is a recently discovered norepinephrine-, dopamine-, and serotonin-reuptake inhibitor, which might have the potential to evoke a weight loss twice that of currently approved drugs (22). A considerable effect of tesofensine on appetite sensations and a moderate effect on energy expenditure at night can contribute to its strong weight-reducing effect (23). The observed weight loss was mainly because of the loss of fat mass and was accompanied by a significant decrease in anthropometric measures of abdominal obesity as the waist circumference and the sagittal abdominal diameter. Beneficial effects of tesofensine administration were demonstrated on the levels of total cholesterol, triglycerides, insulin, adiponectin, and hemoglobin A_{1c}. The most frequently observed adverse events (nausea, dry mouth, constipation, and insomnia) are similar for tesofensine and sibutramine. Increases in pulse rate, but no significant increases in sBP and dBP, were observed after 24-weeks' treatment with tesofensine in a dose of 0.25 or 0.50 mg. However, these findings on the efficacy and safety of tesofensine with regard to its potential adverse effects (cardiovascular and CNS) need confirmation in phase III trials conducted in larger cohorts of obese patients.

IS CETILISTAT THE SUCCESSOR OF ORLISTAT?

The efficacy and safety of cetilistat, a novel inhibitor of gastrointestinal lipases, was determined in both obese nondiabetic (24) and diabetic (25) patients. Similar weight reductions were observed in patients treated with cetilistat and orlistat (25). Weight reductions (from −3.3 kg to −4.3 kg) achieved by the treatment with different doses of cetilistat (60 mg t.i.d., 120 mg t.i.d., 240 mg t.i.d.) over a 12-week period were statistically significant compared with placebo (24,25). The treatment with cetilistat resulted in significant reductions in total and LDL cholesterol levels in obese patients (24) and in an improved glycemic control in obese patients with diabetes (25). Cetilistat treatment was well tolerated and exhibited fewer side effects compared with orlistat. Significantly reduced frequency of gastrointestinal adverse events after cetilistat could be attributable to structural differences between the two molecules and their

interaction with fat micelles in the intestine (25).

LEPTIN: TREATMENT OF RELATIVE LEPTIN DEFICIENCY?

Obesity, metabolic, neuroendocrine, and behavioral consequences of the rare congenital leptin deficiency in humans are efficiently reversed by the treatment with recombinant leptin (26). On the other hand, subjects with common obesity are hyperleptinemic compared with normal weight individuals and resistant to the central hypothalamic effects of endogenous leptin and less sensitive to exogenous leptin (27). However, some obese subjects who have recently lost weight exhibit a relative leptin deficiency and reduced concentrations of thyroid hormones that could be reversed by an administration of exogenous leptin (28). Further studies are needed to support the role of leptin administration for weight maintenance in subjects who develop relative leptin deficiency in response to calorie deficit.

MELANOCORTIN-4 RECEPTOR AGONISTS

In contrast to the rare congenital leptin deficiency, melanocortin-4 receptor (MC4R) mutations are the most common causes of monogenic obesities. MC4R deficiency is responsible for 0.5–2.5% of severe obesities. Two novel MC4R agonists were recently identified that were able in vitro to activate mutated human MC4R (29). However, clinical trials are required to confirm the efficiency and safety of these compounds in humans.

LORCASERIN: A SAFE SUCCESSOR OF DEXFENFLURAMINE?

Dexfenfluramine addressed serotonergic hypothalamic appetite control mechanisms and led to body weight loss, increased adherence to a weight management program, and favorably affected cardiometabolic health risks in both obese nondiabetic (30) and diabetic (31) patients. However the mechanism of dexfenfluramine action—stimulation of serotonin release, inhibition of its reuptake, and direct stimulation of postsynaptic serotonin receptors—was also associated with serious side effects such as valve disease and pulmonary arterial hypertension (32,33). In response to these observations, fenfluramine and dexfenfluramine were voluntarily withdrawn from the market in 1997 (33).

In order to avoid adverse peripheral side effects, a new selective serotonin agonist, lorcaserin, has recently been developed. Lorcaserin selectively activates 5-HT_{2C} receptors, which are located primarily in the hypothalamus, thalamus, and limbic structures and are virtually absent in peripheral tissues. This way, unfavorable cardiovascular side-events are avoided (34). The administration of lorcaserin to obese subjects in both short-term (2 weeks) and long-term (1-year and 2-year) trials resulted in decreased body weight and waist circumference as well as in improved cardiometabolic risk profile and quality of life (35–37). At 1-year follow-up, significantly more patients lost 5% of their body weight in the lorcaserin group than in the placebo group (47.5 vs. 20.3%, $P < 0.001$), corresponding to an average weight loss of 5.8 ± 0.2 kg with lorcaserin and 2.2 ± 0.1 kg with placebo (37). No drug-related effects on heart valves, pulmonary artery pressure, or depression and suicidal ideation were recorded. Transient headache, nausea, and dizziness were the most frequently reported side-effects (35,37).

DRUGS BLOCKING CANNABINOID AND DOPAMINERGIC RECEPTORS

The blockade of cannabinoid CB₁ receptors (with rimonabant or taranabant) and dopaminergic D₁/D₅ receptors (with ecopipam) exerted favorable effects on body weight and cardiometabolic health risks (38–41). However, because of the increased risks of psychiatric adverse events, i.e., depressed mood disorders, anxiety, and suicidal ideation, rimonabant was withdrawn from the obesity treatment (42), and pharmaceutical companies discontinued clinical trials with taranabant and ecopipam as antiobesity agents (40,41). Rimonabant positively influenced dyslipidemia and insulin resistance not only by decreasing the food intake in the brain but also by blocking peripheral CB₁ receptors. CB₁ blockade favorably affects lipogenesis in fat stores and liver, glucose uptake in skeletal muscle, and adiponectin secretion in adipose tissue.

Knowledge of peripheral targets of CB₁ antagonists led to the development of a new CB₁ antagonist, TM38837, which specifically acts in the peripheral tissues because of the lowered propensity to pass the blood-brain barrier (43). The phase I clinical trial with TM38837 was successfully

completed in 2009 (J.M. van Gerver, unpublished results).

COMBINATION DRUGS—Approaches with two drug combinations of decreased doses were recommended to increase both the safety and efficacy of antiobesity treatment. However combinations of sibutramine and orlistat exhibited no advantages over the monotherapy with sibutramine alone (44,45). Combining fenfluramine and phentermine was aimed to achieve fewer adverse events and better appetite control (46). This drug combination, quite efficient in terms of weight loss and thus widely prescribed (over 18 million prescriptions in the U.S. in 1996!), was later shown to be associated with an increased risk of valvular heart disease (32). Phentermine interferes with the clearance of serotonin, and this way a combination of fenfluramine and phentermine may potentiate the untoward effects of circulating serotonin and result in valvular injury similar to that seen in patients with carcinoid syndrome (32).

Recently, several new drug combinations were investigated. The antidepressant bupropion, which acts as norepinephrine and dopamine reuptake inhibitor and melanocortin pathways stimulator, was combined with the opioid antagonist naltrexone, which antagonized proopiomelanocortin neurons inhibition by endogenous opioids. A sustained-release (SR) combination of naltrexone and bupropion was well tolerated and produced synergistic weight loss, which significantly exceeded that induced by placebo or by either drug alone (47,48). Naltrexone SR/bupropion SR (NB) combination therapy as an adjunct to behavior modification applied for 56 weeks induced significantly greater weight loss compared with behavior modification alone ($9.3 \pm 0.4\%$ vs. $5.1 \pm 0.6\%$, $P < 0.001$) (49). NB treatment was associated with improvements in body fat distribution, lipid profile, glucose homeostasis, and quality of life (49). The most frequent adverse event in response to NB treatment was nausea. NB combination treatment was not associated with increased depression and suicide attempts. Moreover, those using NB combination treatment exhibited fewer adverse psychiatric events than those using its components given separately (48,50). Transient increases in both sBP and dBP during the initial phase of NB treatment should however be carefully evaluated in future studies (48,50).

The addition of amylin (pramlantide) to leptin (metreleptin) restores leptin responsiveness in subjects with common obesity and after 12-months' treatment results in significant weight loss (-11.5 kg), reduction in triglycerides (-8%), total cholesterol (-8%), fasting blood glucose (-4 mg/dL), insulinemia (-22%), and insulin resistance/homeostasis model assessment (-25%) (51). However, these combinations of antiobesity agents as well as other recently developed combinations—bupropion and zonisamide, phentermine and topiramate, pramlantide and sibutramine (52), pramlantide and phentermine (52)—require further long-term studies and a careful evaluation with regard to their efficacy and potential adverse events (53). Combination therapies using phentermine should consider that an administration of phentermine is recommended for a short-term period only.

GUT HORMONES—Several hormones of the gastrointestinal tract such as glucagon-like peptide 1 (GLP-1), cholecystikinin, amylin, pancreatic polypeptide, peptide YY (PYY_{3–36}), oxyntomodulin (OXM), and ghrelin have been found to play important roles in energy balance regulation, and some have recently been investigated as pharmaceutical targets for obesity (54). The administration of physiological doses of gut-derived appetite-regulating agents is expected to be an efficient, specific, and thus a low side-effect approach in the treatment of obesity.

The GLP-1 is secreted from L-cells of the intestine in response to a meal. GLP-1 suppresses elevated glucagon secretion by pancreatic β -cells, enhances insulin secretion, decreases apoptosis in pancreatic β -cells, increases satiety in the brain, and delays gastric emptying. Postprandial GLP-1 secretion is reduced in diabetic patients compared with nondiabetic patients. GLP-1 receptor agonists such as liraglutide and exenatide represent a new treatment option for patients with diabetes, and especially those who are obese. A recent review of randomized controlled trials evaluated six trials with exenatide and six trials with liraglutide that were administered either alone or combined with oral antidiabetic drugs (55). Both drugs improved glycemic control, induced comparable weight losses, and reduced blood pressure (55). The most frequent side effects were transient mild nausea and minor hypoglycemia, which were less common with liraglutide

than with exenatide (56). Antibodies developed with a lesser frequency in liraglutide-treated subjects than in those treated by exenatide, likely because of its greater structural similarity with human GLP-1 (97 vs. 52%). However, it is encouraging that the development of antibodies does not affect the drug efficacy. Combining GLP-1 analogs with metformin in obese patients with diabetes seems a reasonable approach, as both drugs possess the weight-lowering properties (57,58). The disadvantage of GLP-1 agonists is a need for parenteral administration—once daily with liraglutide and twice daily with exenatide. A recent study demonstrated that a long-term version of exenatide administered once weekly produced sustained glycemic control and weight loss over 52 weeks (59). Other recently developed GLP-1 agonists with prolonged half-lives such as tasoglutide and albiglutide may also allow weekly dosing.

Several trials evaluating the use of GLP-1 agonists as antiobesity drugs have been in progress. Only a few of the results have been published. A small-scale study conducted in overweight nondiabetic women with polycystic ovary syndrome demonstrated that a combination of exenatide with metformin favorably influenced body weight, insulin sensitivity, and menstrual cyclicity. These beneficial effects were more pronounced with combination treatment than with administration either of exenatide or metformin alone (60).

Other gut hormones (e.g., amylin, OXM, PYY₃₋₃₆) as potential antiobesity drugs are currently being investigated (61). Amylin is cosecreted with insulin by pancreatic β -cells in response to meal intake. Amylin inhibits food intake in the area postrema via specific amylin receptors, regulates gastric emptying, and suppresses inappropriate postprandial glucagon secretion. Sustained weight loss of 7.2 kg in response to a 12-month treatment with synthetic amylin analog pramlintide (360 μ g twice daily) was demonstrated in obese and relatively healthy subjects (62). The most common side effect with pramlintide treatment was mild nausea. Both OXM and PYY₃₋₃₆ are cosecreted with GLP-1 from intestinal L-cells. OXM inhibits food intake in the hypothalamus by binding to three different receptors (GLP-1 receptor, glucagon receptor, and independent OXM receptor). Only preliminary data on energy intake, energy expenditure, and weight loss in humans after OXM and PYY₃₋₃₆ have

been available (61). The less frequent nausea after administration of OXM than after GLP-1 agonists encourages further clinical studies. To improve clinical usefulness of treatment, the breakdown-resistant analogs of OXM and intranasally administered analogs of PYY₃₋₃₆ have been developed. A recently published study suggested that the anorectic effect of PYY₃₋₃₆ and OXM can be additive (63). Coadministration of PYY₃₋₃₆ and OXM intravenously reduced energy intake by 42.7% in comparison with saline control. This energy intake reduction after combined hormone administration was more pronounced than during infusions of either hormone alone.

DURATION OF TREATMENT WITH ANTI-OBESITY DRUGS

Long-term administration of antiobesity drugs should be indicated according to the weight loss achieved in response to an initial 3-months' therapy (64,65). A meta-analysis of sibutramine studies revealed that a weight loss of 4 kg at 3 months predicted weight loss >5% at 12 months (65). The drug administration should be discontinued in patients who do not respond to 3-months' drug treatment. It has been demonstrated that intermittent treatment with some antiobesity drugs (phentermine, sibutramine) may be as effective as their continuous administration and may diminish both the side effects and costs (66,67). On the other hand, the long-term replacement of antiobesity drugs with placebo is followed by weight regain as demonstrated in the studies with sibutramine, lorcaserin, and rimonabant conducted over a 2-year period (5,37,39). It therefore should be considered that future drug treatment of obesity should be indicated for lifelong administration as in treating other complex diseases.

CONCLUSIONS—Currently available antiobesity drugs result in only modest weight loss accompanied by reductions of cardiometabolic health risks. Adverse events related to existing antiobesity drugs however, call for careful assessment of the risk/benefit profile in each new agent designed to treat obesity. Further studies evaluating the effect of antiobesity drugs on morbidity and mortality end points in appropriate target populations are needed. It is expected that the new compounds, which have recently been tested in clinical trials, will possess more advantages over the currently

available agents both with regard to their efficacy and safety (68). However, it will be necessary for medical authorities to persuade not only physicians and patients but also the drug-regulating agencies (and their committees) that the drug treatment of obesity (de facto obesity) must evaluate antiobesity drugs just as they do those for other complex diseases (such as hypertension) and take into account their specific pathogenesis and character, age of a patient, and presence of comorbidities (69).

ADDENDUM—On October 8, 2010, the following statement was released by the Abbott Laboratories: “Abbott believes sibutramine has a positive risk/benefit profile in the approved patient population, but will comply with the FDA’s [Food and Drug Administration’s] request and will voluntarily withdraw Meridia® (sibutramine) from the U.S. market.”

Acknowledgments—This study was partly supported by a grant from the Czech Ministry of Health (IGA NR/7800-4). V.H. participated as an investigator in the SCOUT Study supported by the Abbott Laboratories. No other potential conflicts of interest relevant to this article were reported.

References

1. World Health Organization. *Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation*. Geneva, World Health Org., 2000 (Tech. Rep. Ser., no. 894)
2. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary 1–3: Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. *Am J Clin Nutr* 1998;68:899–917
3. Tsigos C, Hainer V, Basdevant A, et al.; Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. *Obes Facts* 2008;1:106–116
4. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? *Diabetes Care* 2008;31(Suppl. 2):S269–S277
5. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. *STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance*. *Lancet* 2000; 356:2119–2125

6. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 2004;27:155–161
7. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. *BMJ* 2007;335:1194–1199
8. Neovius M, Johansson K, Rössner S. Head-to-head studies evaluating efficacy of pharmacotherapy for obesity: a systematic review and meta-analysis. *Obes Rev* 2008;9:420–427
9. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. *Arch Intern Med* 2004;164:1395–1404
10. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. *Obes Rev* 2009;10:333–341
11. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. *Int J Obes Relat Metab Disord* 1999;23:1016–1024
12. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. *Int J Obes (Lond)* 2005;29:509–516
13. Johansson K, Sundström J, Neovius K, Rössner S, Neovius M. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. *Obes Rev* 2010;11:777–791
14. Scheen A. Sibutramine on cardiovascular outcome. *Diabetes Care* 2011;34(Suppl. 2):S114–S119
15. James WPT, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med* 2010;363:905–917
16. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. *Vasc Health Risk Manag* 2009;5:441–452
17. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. *Vasc Health Risk Manag* 2007;3:817–821
18. Coutinho W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. *Arq Bras Endocrinol Metabol* 2009;53:262–270
19. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. *Am J Manag Care* 2001;7:875–883
20. Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. *Int J Obes (Lond)* 2005;29:208–216
21. Elfhag K, Finer N, Rössner S. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. *Diabetes Obes Metab* 2008;10:498–505
22. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;372:1906–1913
23. Sjödin A, Gasteyer C, Nielsen AL, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. *Int J Obes (Lond)* 2010;34:1634–1643
24. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. *Int J Obes (Lond)* 2007;31:494–499
25. Kopelman P, Groot GdeH, Rissanen A, et al. Weight loss, HbA_{1c} reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). *Obesity (Silver Spring)* 2010;18:108–115
26. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. *N Engl J Med* 1999;341:879–884
27. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. *Annu Rev Physiol* 2008;70:537–556
28. Rosenbaum M, Goldsmith R, Bloomfield D, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. *J Clin Invest* 2005;115:3579–3586
29. Roubert P, Dubern B, Plas P, et al. Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. *J Endocrinol* 2010;207:177–183
30. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. *Obes Res* 1995;3(Suppl. 4):491S–496S
31. Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS. Dexfenfluramine in obese Chinese NIDDM patients: a placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. *Diabetes Care* 1997;20:1122–1127
32. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. *N Engl J Med* 1997;337:581–588
33. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. *JAMA* 2000;283:1703–1709
34. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine_{2C} agonist: in vitro and in vivo pharmacological characterization. *J Pharmacol Exp Ther* 2008;325:577–587
35. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR; APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT_{2C} agonist, reduces body weight in obese men and women. *Obesity (Silver Spring)* 2009;17:494–503
36. Anderson CM, Smith SR, Sanchez M, Stubbe S, Shanahan WR. Lorcaserin treatment was associated with improvements in cardiovascular risk factors and weight loss in the BLOOM trial. *Obesity (Silver Spring)* 2009;17(Suppl. 2):S52
37. Smith SR, Weissman NJ, Anderson CM, Shanahan WR; the Behavioral Modification and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. *N Engl J Med* 2010;363:245–256
38. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. *Lancet* 2005;365:1389–1397
39. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. *JAMA* 2006;295:761–775
40. Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. *Int J Obes (Lond)* 2010;34:919–935
41. Astrup A, Greenway FL, Ling W, et al.; for the Ecopipam Obesity Study Group. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. *Obesity (Silver Spring)* 2007;15:1717–1731
42. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet* 2007;370:1706–1713

43. Receveur JM, Murray A, Linget JM, et al. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. *Bioorg Med Chem Lett* 2010; 20:453–457
44. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. *Obes Res* 2000;8:431–437
45. Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. *Endocr Res* 2004;30:159–167
46. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. *Arch Intern Med* 1984;144:1143–1148
47. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. *Obesity (Silver Spring)* 2009;17:30–39
48. Greenway FL, Fujioka K, Plodkowski RA, et al.; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2010;376:595–605
49. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. *Obesity (Silver Spring)* 2011;19:110–120
50. Astrup A. Is cardiometabolic risk improved by weight-loss drugs? *Lancet* 2010;376:567–568
51. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. *Obesity (Silver Spring)* 2009;17:1736–1743
52. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. *Obesity (Silver Spring)* 2010; 18:1739–1746
53. Klonoff DC, Greenway F. Drugs in the pipeline for the obesity market. *J Diabetes Sci Tech* 2008;2:913–918
54. Field BC, Chaudhri OB, Bloom SR. Obesity treatment: novel peripheral targets. *Br J Clin Pharmacol* 2009;68:830–843
55. White J. Efficacy and safety of incretin based therapies: clinical trial data. *J Am Pharm Assoc (2003)* 2009;49(Suppl. 1): S30–S40
56. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet* 2009;374:39–47
57. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005;28:1092–1100
58. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care* 2009;32:84–90
59. Buse JB, Drucker DJ, Taylor KL, et al.; DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. *Diabetes Care* 2010;33:1255–1261
60. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2008;93:2670–2678
61. Chaudhri OB, Wynne K, Bloom SR. Can gut hormones control appetite and prevent obesity? *Diabetes Care* 2008;31(Suppl. 2): S284–S289
62. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. *Diabetes Care* 2008;31:1816–1823
63. Field BC, Wren AM, Peters V, et al. PYY₃₋₃₆ and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. *Diabetes* 2010;59:1635–1639
64. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. *Diabetes Obes Metab* 2005;7: 699–708
65. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. *Diabetes Obes Metab* 2006;8: 206–213
66. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. *BMJ* 1968;1:352–354
67. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. *JAMA* 2001;286:1331–1339
68. Astrup A. Drug management of obesity—efficacy versus safety. *N Engl J Med* 2010; 363:288–290
69. Dvorak RV, Sharma AM, Astrup A. Anti-obesity drugs: to be or not to be? *Obes Rev* 2010;11:833–834